Psychiatric side effects such as depression and anxiety have been reported with 26 percent of patients given Acomplia (rimonabant) compared to 14 percent of those given a placebo according to an analysis by Arnie Astrup and others from the University of Copenhagen in Frederiksberg, Denmark.
This is despite the fact that “[all of] the included trials excluded patients with existing depression, or those with a history [of depression],” as Astrup noted.
© Copyright 2003-2012 - Larry Hobbs - All Rights Reserved.